Pugilistic Vanda Collects Another NOOH As US FDA Defends Tradipitant Turndown

 
• By Bridget Silverman

Vanda’s fight against a complete response letter for its gastroparesis drug results in a notice of opportunity for hearing on a formal FDA proposal to refuse to approve the NDA.

Can Vanda revive its bid for tradipitant after the FDA revealed its case for refusing approval? (Shutterstock)

More from Complete Response Letters

More from Pathways & Standards